(Q45016242)

English

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

0 references

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

10.1038/LEU.2008.288

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/LEU.2008.288

Efstathios Kastritis

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Athanasios Dimopoulos

10

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

E Eleftherakis-Papaiakovou

7

object named as

E Eleftherakis-Papaiakovou

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

E Terpos

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

M Roussou

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

D Heath

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

D Christoulas

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

N Anagnostopoulos

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

K Tsionos

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

P Croucher

9

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

4 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

2247-2256

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

The role of markers of bone remodeling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

21 January 2018

Granulocyte colony-stimulating factor mobilized CFU-F can be found in the peripheral blood but have limited expansion potential

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

21 January 2018

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to bortezomib and activation of osteoblasts in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloma bone disease and proteasome inhibition therapies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.235

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2008.235

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45016242&oldid=2207047661"